Indeed, the anti-CD11a monoclonal antibody (mAb) efalizumab was used to treat autoimmune diseases, including psoriasis and psoriatic arthritis, and was tested in rheumatoid arthritis (Table S2) before being withdrawn for safety issues. This evidence concerns the gene ITGAL and psoriasis.